Topoisomerase II Immunostaining as a Prognostic Marker for Survival in Ovarian Cancer
- 1 July 2001
- journal article
- research article
- Published by Elsevier in Gynecologic Oncology
- Vol. 82 (1), 99-104
- https://doi.org/10.1006/gyno.2001.6208
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Age as a prognostic factor in ovarian carcinoma: The gynecologic oncology group experienceCancer, 2010
- Immunophenotype of Ovarian Cancer as Predictor of Clinical Outcome: Evaluation at Primary Surgery and Second-Look ProcedureGynecologic Oncology, 1998
- Oncogene Expression: Long-Term Compared With Short-Term Survival in Patients With Advanced Epithelial Ovarian CancerObstetrics & Gynecology, 1998
- The clinical predictivity of biomarkers of stage III-IV epithelial ovarian cancer in a prospective randomized treatment protocolCancer, 1998
- p53 Expression in Epithelial Ovarian Neoplasms: Relationship to Clinical and Pathological Parameters, Ki-67 Expression and Flow CytometryGynecologic Oncology, 1994
- Determination of Proliferation Index with MIB-1 in Advanced Ovarian Cancer Using Quantitative Image AnalysisAmerican Journal of Clinical Pathology, 1994
- Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience.Journal of Clinical Oncology, 1991
- Steroid receptors and Ki‐67 reactivity in ovarian cancer and in normal ovary: Correlation with dna flow cytometry, biochemical receptor assay, and patient survivalThe Journal of Pathology, 1990
- Hormonal Responses to Large Paracentesis: Are Discordant Results Due to Technologic Differences?Hepatology, 1990
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian CancerScience, 1989